National Institute of General Medical Sciences; Notice of Closed Meeting, 22501-22502 [2018-10356]
Download as PDF
Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Use of the CD47
Phosphorodiamidate Morpholino
Oligomers for the Treatment,
Prevention, and Diagnosis of
Hematological Cancers
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to Morphiex
Biotherapeutics (‘‘Morphiex’’) located in
Boston, MA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before May 30, 2018 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Jaime M. Greene, Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702 Telephone: (240) 276–5530;
Facsimile: (240)–276–5504 Email:
greenejaime@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
Intellectual Property
1. U.S. Provisional Patent Application
No. 60/850,132, filed October 6, 2006,
now abandoned (HHS Ref. No. E–227–
2006/0–US–01);
2. U.S. Provisional Patent Application
No. 60/864,153, filed November 02,
2006, now abandoned (HHS Ref. No. E–
227–2006/1–US–01);
3. U.S. Provisional Patent Application
No. 60/888,754, filed February 07, 2007,
now abandoned (HHS Ref. No. E–227–
2006/2–US–01);
4. U.S. Provisional Patent Application
No. 60/910,549, filed April 06, 2007,
now abandoned (HHS Ref. No. E–227–
2006/3–US–01);
5. U.S. Provisional Patent Application
No. 60/956,375, filed August 16, 2007,
now abandoned (HHS Ref. No. E–227–
2006/4–US–01);
VerDate Sep<11>2014
20:27 May 14, 2018
Jkt 244001
6. PCT Patent Application No. PCT/
2007/080647, filed October 5, 2007, now
abandoned (HHS Ref. No. E–227–2006/
5–PCT–01);
7. U.S. Patent No. 8,236,313, filed
April 3, 2009, Issued August 7, 2012
(HHS Ref. No. E–227–2006/5–US–02);
8. Canadian Patent Application No.
2,665,287, October 5, 2007 (HHS Ref.
No. E–227–2006/5–CA–03);
9. Australian Patent No. 2007319576,
filed October 5, 2007, Issued May 1,
2014 (HHS Ref. No. E–227–2006/5–AU–
04);
10. European Patent Application No.
07868382.8, filed March 27, 2009 (HHS
Ref. No. E–227–2006/5–EP–05);
11. U.S. Patent Application No. 13/
546,931, filed July 11, 2012 (HHS Ref.
No. E–227–2006/5–US–06);
12. U.S. Patent Number 8,557,788,
filed July 11, 2012, Issued October 15,
2013 (HHS Ref. No. E–227–2006/5–US–
07);
13. European Patent Application No.
13180563.2, filed October 5, 2007 (HHS
Ref. No. E–227–2006/5–EP–08);
14. Australian Patent No. 2014201936,
filed October 5, 2007, Issued October 20,
2016 (HHS Ref. No. E–227–2006/5–AU–
09);
15. U.S. Patent Application No. 14/
500,861, filed September 29, 2014 (HHS
Ref. No. E–227–2006/5–US–10);
16. Australian Patent No. 2016238894,
filed October 6, 2016, Issued February
22, 2018 (HHS Ref. No. E–227–2006/5–
AU–11);
17. Australian Patent Application No.
2018200921, filed February 8, 2018
(HHS Ref. No. E–227–2006/5–AU–12).
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to ‘‘the use
of the CD47 phosphorodiamidate
morpholino oligomers (PMO,
morpholino, Sequence: 5′CGTCACAGGCAGGACCCACTGCCCA3′) for the treatment, prevention, and
diagnosis of hematological cancers (e.g.
lymphoma, leukemia, multiple
myeloma), excluding uses in
combination with radiotherapy.’’
This technology concerns CD47,
originally named integrin-associated
protein, which is a receptor for
thrombospondin-1(TSP–1), a major
component of platelet a-granules from
which it is secreted on platelet
activation. A number of important roles
for CD47 have been defined in
regulating the migration, proliferation,
and survival of vascular cells, and in
regulation of innate and adaptive
immunity. Nitric Oxide (NO) plays an
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
22501
important role as a major intrinsic
vasodilator, and increases blood flow to
tissues and organs. Disruption of this
process leads to peripheral vascular
disease, ischemic heart disease, stroke,
diabetes and many more significant
diseases. The inventors have discovered
that TSP1 blocks the beneficial effects of
NO, and prevents it from dilating blood
vessels and increasing blood flow to
organs and tissues. Additionally, they
discovered that this regulation requires
TSP1 interaction with its cell receptor,
CD47. These inventors have also found
that blocking TSP1–CD47 interaction
through the use of antisense morpholino
oligonucleotides, peptides, or antibodies
has several therapeutic benefits
including the treatment of cancer.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: April 30, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2018–10238 Filed 5–14–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
E:\FR\FM\15MYN1.SGM
15MYN1
22502
Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Support of Competitive
Research (SCORE) Award Applications.
Date: July 12, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Saraswathy Seetharam,
Scientific Review Officer, Office Scientific
Review, National Institute of General Medical
Sciences, National Institutes Health, 45
Center Drive, Room 3AN12C, Bethesda, MD
20892, 301–594–2763, seetharams@
nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: May 10, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–10356 Filed 5–14–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
daltland on DSKBBV9HB2PROD with NOTICES
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
VerDate Sep<11>2014
20:27 May 14, 2018
Jkt 244001
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Training
Grants.
Date: June 8, 2018.
Time: 3:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892.
Contact Person: Jeannette L. Johnson,
Ph.D., National Institutes on Aging, National
Institutes of Health, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892, 301–402–
7705, johnsonj9@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: May 10, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–10353 Filed 5–14–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Tissue Chip Testing Center
(TCTC) & Data Centers (DC).
Date: June 13, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Barbara J. Nelson, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences (NCATS), National
Institutes of Health 6701 Democracy Blvd.,
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Democracy 1, Room 1080, Bethesda, MD
20892–4874, nelsonbj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: May 9, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–10234 Filed 5–14–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental and
Craniofacial Research; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; NIDCR DSR Member
Conflict SEP.
Date: June 5, 2018.
Time: 12:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Marilyn Moore-Hoon,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute of Dental
and Craniofacial Research, 6701 Democracy
Blvd., Rm. 676, Bethesda, MD 20892–4878,
301–594–4861, mooremar@nidcr.nih.gov.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; NIDCR Clinical Research
Grant Reviews.
Date: June 6, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892.
E:\FR\FM\15MYN1.SGM
15MYN1
Agencies
[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)]
[Notices]
[Pages 22501-22502]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10356]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
[[Page 22502]]
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel; Review of Support of Competitive
Research (SCORE) Award Applications.
Date: July 12, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn Bethesda, 7301 Waverly Street,
Bethesda, MD 20814.
Contact Person: Saraswathy Seetharam, Scientific Review Officer,
Office Scientific Review, National Institute of General Medical
Sciences, National Institutes Health, 45 Center Drive, Room 3AN12C,
Bethesda, MD 20892, 301-594-2763, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.375,
Minority Biomedical Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology, Physiology, and
Biological Chemistry Research; 93.862, Genetics and Developmental
Biology Research; 93.88, Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859, Biomedical Research and
Research Training, National Institutes of Health, HHS)
Dated: May 10, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-10356 Filed 5-14-18; 8:45 am]
BILLING CODE 4140-01-P